Université de Sherbrooke
usherbrooke.caTotal trials
293
Active
72
Phase 3
15
Total enrollment
59,408
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 18 of 18 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| 1- Vasopressor - Mean arterial pressure 56-60 | — | — | — | — | — | 1 | |
| 2- Vasopressor - Mean arterial pressure 61-65 | — | — | — | — | — | 1 | |
| 3- Vasopressor - Mean arterial pressure 66-70 | — | — | — | — | — | 1 | |
| 4- Vasopressor - Mean arterial pressure 71-75 | — | — | — | — | — | 1 | |
| Androgen blockade + radiation therapy | — | — | — | — | — | 1 | |
| Dupilumab Prefilled Syringe | — | — | — | — | — | 1 | |
| CBD Oral Solution | — | — | — | — | — | 2 | |
| IA Carboplatin + IA Caelyx | — | — | — | — | — | 1 | |
| IA Carboplatin + IA Etoposide Phosphate | — | — | — | — | — | 1 | |
| Tacrolimus | — | — | — | — | — | 1 | |
| Celecoxib | — | — | — | — | — | 1 | |
| IA Carbo+ Radiation | — | — | — | — | — | 1 | |
| 89Zr-DFO-AP-101 | — | — | — | — | — | 1 | |
| Nicotinic Acid | — | — | — | — | — | 2 | |
| Antipsychotic drugs | — | — | — | — | — | 1 | |
| Niacin | — | — | — | — | — | 1 | |
| Fluconazole 150 mg | — | — | — | — | — | 1 | |
| Heparin | — | — | — | — | — | 1 |
Next readouts
- 2024-12-30
- 2025-12
- 2025-12-10
- 2026-11-01
- 2026-12-15
- 2026-12-30
- 2026-12-31
- 2027-04
- 2027-12-01
- 2027-12-15
Top conditions
- Healthy14
- Chronic Pain13
- Obesity12
- Type 2 Diabetes9
- Stroke7
- Gestational Diabetes Mellitus6
- Asthma5
- Overweight4
Frequently asked questions about Université de Sherbrooke
- How many clinical trials does Université de Sherbrooke have on ClinicalTrials.gov?
- Université de Sherbrooke is listed as the lead sponsor on 293 clinical trials in ClinicalTrials.gov, 72 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Université de Sherbrooke's trials are in Phase 3?
- 15 of Université de Sherbrooke's trials are in Phase 3, spread across 18 active drug programs.
- What therapeutic areas does Université de Sherbrooke focus on?
- Université de Sherbrooke's most-studied conditions on ClinicalTrials.gov are Healthy, Chronic Pain, Obesity, Type 2 Diabetes, Stroke.
- When are Université de Sherbrooke's next clinical trial readouts?
- Université de Sherbrooke has 10 upcoming primary-completion readouts tracked here; the soonest is “Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated With Amyotrophic Lateral Sclerosis”, expected around 2024-12-30.